Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin

Bone Marrow Transplantation

Volumn 23, Issue 11, 1999, Pages 1139-1143

  Weiss, L ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anti CD4; Anti CD8; Graft versus host disease; Veto cells

Indexed keywords

CD8 ANTIGEN; OKT 4; OKT 8; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHIMERA; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HOST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; WHOLE BODY RADIATION;

EID: 0032973061     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701784     Document Type: Article

References (25)

1. Ringden O, Horowitz MM for the Advisory Committee of the International BMT Registry. Graft-versus-leukemia reactions in humans. Transplant Proc 1989; 21: 2989-2992.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T cell depletion with CAMPATH 1 reduces the incidence of GVHD but may increase the risk of leukemic relapse. Bone Marrow Transplant 1986; 1: 53-60.
4. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
5. Martin PJ, Hansen JA, Torok-Storb B et al. Graft failure in patients receiving T cell depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988; 3: 445-456.
6. Waldmann H, Polliak A, Hale G, Or R et al. Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes with monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-485.
7. Weiss L, Reich S, Slavin S. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 6: 229-233.
8. Bacigalupo A, Van Lint MT, Occhini D et al. Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
9. Collins RH, Rogers ZR, Bennett M et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391-395.
10. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990; 50: 175-177.
11. Chiang KY, Weisdorf DJ, Davies SM et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 1996; 17: 39-42.
12. Slavin S. Total lymphoid irradiation (TLI). Immunol Today 1987; 8: 88-92.
13. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 169-175.
14. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F1 hybrid mice. J Exp Med 1971; 134: 1513-1528.
15. Nagler A, Lanier LL, Cwirla S et al. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143: 3183-3191.
16. Slavin S, Fuks Z, Kaplan HS et al. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med 1978; 147: 963-972.
17. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts and xenografts. Nature 1984; 307: 168-170.
18. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988; 9: 23-27.
19. Billingham RE, Brent L, Medawar BP. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603.
20. Starzl TE, Demetris AJ, Murase EN et al. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579-1582.
21. Sun J, McCaughan GW, Gallagher ND et al. Deletion of spontaneous rat liver allograft acceptance by donor irradiation. Transplantation 1995; 60: 233-236.
22. Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 1981; 11: 155-158.
23. Sykes M, Romick ML, Sachs DH. Interleukin 2 prevents graft-vs-host disease while preserving the graft-vs-leukemia effect of allogeneic T cells. Proc Natl Acad Sci USA 1990; 87: 5633-5637.
24. Knapp MR, Jones PP, Black SJ et al. Characterization of a spontaneous murine B cell leukemia (BCL1). 1. Cell surface expression of IgM, IgD, Ia and FcR. J Immunol 1979; 123: 992-999.
25. Weiss L, Lubin I, Factorowich I et al. Effective graft vs leukemia effects independent of graft vs host disease after T cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol 1994; 153: 2562-2567.